Katja Zimmermann, Martin Hossann, Johannes Hirschberger, Karin Troedson, Michael Peller, Moritz Schneider, Andreas Brühschwein, Andrea Meyer-Lindenberg, Gerhard Wess, Melanie Wergin, René Dörfelt, Thomas Knösel, Markus Schwaiger, Christine Baumgartner, Johanna Brandl, Sabine Schwamberger, Lars H Lindner
PURPOSE: Doxorubicin (DOX)-loaded phosphatidyldiglycerol-based thermosensitive liposomes (DPPG2-TSL-DOX) combined with local hyperthermia (HT) were evaluated in cats with locally advanced spontaneous fibrosarcomas (soft tissue sarcoma, STS). The study was designed to evaluate the safety and pharmacokinetic profile of the drug. Results from four dose-levels are reported. METHODS: Eleven client-owned cats with advanced STS were enrolled. Five cats received escalating doses of 0...
September 4, 2016: International Journal of Hyperthermia